Cardiovascular complications and their association with short- and long-term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T-cell therapy

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Leukemia

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Leukemia

Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z

doi: 10.1038/s41375-024-02467-5

Lymphoma

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Br J Haematol

Hossain NM, Ahn KW, Patel J, Lian Q, Abid B, Al Nughmush A, Bacher U, Bi X, Hashmi SK, Hilal T, Husnain M, Khimani F, Maziarz RT, Modi D, Ram R, Rizzieri D, Sica RA, Steinberg A, Vij R, Shadman M, Turtle C, Hamadani M, Herrera AF

doi: 10.1111/bjh.70020

Leukemia

Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy

Leuk Lymphoma

Bindal P, Trottier CA, Elavalakanar P, Dodge LE, Kim S, Logan E, Ma S, Liegel J, Arnason J, Alonso CD

doi: 10.1080/10428194.2024.2439513

Multiple Myeloma (MM)

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Leuk Lymphoma

Park H, Robinson J, Flanagan C, Pawlyn C, Jackson G, Jones JR

doi: 10.1080/10428194.2025.2560085

Further Publications

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

Haematologica

Boardman AP, Gutgarts V, Flynn J, Devlin SM, Goldman A, Tomas AA, Fein JA, Slingerland JB, Parascondola A, Lin RJ, Scordo M, Dahi PB, Giralt S, Palomba ML, Salles G, Nath K, Walji M, Corona M, Park JH, Shah GL, Perales MA, Jaffer-Sathick I, Shouval R

doi: 10.3324/haematol.2024.286021

Multiple Myeloma (MM)

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood

Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, Wäsch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kröger N

doi: 10.1182/blood.2025028330

Lymphoma

Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

Br J Haematol

Barone A, De Philippis C, Stella F, Dodero A, Sarina B, Pennisi M, Santoro A, Carlo-Stella C, Guidetti A, Bramanti S, Corradini P

doi: 10.1111/bjh.70010

Further Publications

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

Blood Cancer J

Einarsdottir S, Lobaugh S, Luan D, Gomez-Llobell M, Subramanian P, Devlin S, Chung D, Dahi PB, Falchi L, Giralt S, Landau H, Lesokhin AM, Lin R, Lue J, Mailankody S, Palomba ML, Park JH, Salles G, Scordo M, Escribano-Serrat S, Sanz J, Rejeski K, Shouval R, Usmani S, Perales MA, Shah G, Shahid Z

doi: 10.1038/s41408-025-01321-w

Related content

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS

Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies